耐药肺结核短程治疗方案面临的困难与挑战

doi:10.19982/j.issn.1000-6621.20240370

摘要/Abstract

中图分类号:

李琦, 聂文娟, 初乃惠. 耐药肺结核短程治疗方案面临的困难与挑战[J]. 中国防痨杂志, 2024, 46(11): 1297-1302. doi: 10.19982/j.issn.1000-6621.20240370

Li Qi, Nie Wenjuan, Chu Naihui. Difficulties and challenges faced by short-term treatment regimen for drug-resistant pulmonary tuberculosis[J]. Chinese Journal of Antituberculosis, 2024, 46(11): 1297-1302. doi: 10.19982/j.issn.1000-6621.20240370

参考文献 42

[1]	Nahid P, Dorman SE, Alipanah N, et al. Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis. Clin Infect Dis, 2016, 63(7): e147-e195. doi:10.1093/cid/ciw376.
[2]	Peloquin CA. Pharmacology of the antimycobacterial drugs. Med Clin North Am, 1993, 77(6): 1253-1262. doi:10.1016/s0025-7125(16)30191-2.
[3]	World Health Organization. WHO consolidated guidelines on drug-resistant tuberculosis treatment. Geneva: World Health Organization, 2019.
[4]	中华医学会结核病学分会. 中国耐多药和利福平耐药结核病治疗专家共识(2019年版). 中华结核和呼吸杂志, 2019, 42(10): 733-749. doi:10.3760/cma.j.issn.1001-0939.2019.10.006.
[5]	Nahid P, Mase SR, Migliori GB, et al. Treatment of Drug-Resistant Tuberculosis. An Official ATS/CDC/ERS/IDSA Clinical Practice Guideline. Am J Respir Crit Care Med, 2019, 200(10): e93-e142. doi:10.1164/rccm.201909-1874ST.
[6]	Günther G, Ruswa N, Keller PM. Drug-resistant tuberculosis: advances in diagnosis and management. Curr Opin Pulm Med, 2022, 28(3):211-217. doi:10.1097/MCP.0000000000000866. pmid: 35220372
[7]	Lee M, Lee J, Carroll MW, et al. Linezolid for treatment of chronic extensively drug-resistant tuberculosis. N Engl J Med, 2012, 367(16): 1508-1518. doi:10.1056/NEJMoa1201964.
[8]	中华医学会结核病学分会, 抗结核新药贝达喹啉临床应用专家共识编写组. 抗结核新药贝达喹啉临床应用专家共识. 中华结核和呼吸杂志, 2018, 41(6): 461-466. doi:10.3760/cma.j.issn.1001-0939.2018.06.005.
[9]	胡旭. 临床医院抗菌药物应用及细菌耐药情况研究. 咸宁: 湖北科技学院, 2020. doi:10.27862/d.cnki.ghkxy.2020.000019.
[10]	Mirzayev F, Viney K, Linh NN, et al. World Health Organization recommendations on the treatment of drug-resistant tuberculosis, 2020 update. Eur Respir J, 2021, 57(6): 2003300. doi:10.1183/13993003.03300-2020.
[11]	Borisov SE, Dheda K, Enwerem M, et al. Effectiveness and safety of bedaquiline-containing regimens in the treatment of MDR- and XDR-TB: a multicentre study. Eur Respir J, 2017, 49(5): 1700387. doi:10.1183/13993003.00387-2017.
[12]	Perrineau S, Lachatre M, Lê MP, et al. Long-term plasma pharmacokinetics of bedaquiline for multidrug- and extensively drug-resistant tuberculosis. Int J Tuberc Lung Dis, 2019, 23(1): 99-104. doi:10.5588/ijtld.18.0042. pmid: 30674381
[13]	Zhu H, Xie L, Liu ZQ, et al. Population pharmacokinetics of bedaquiline in patients with drug-resistant TB. Int J Tuberc Lung Dis, 2021, 25(12):1006-1012. doi:10.5588/ijtld.21.0158. pmid: 34886931
[14]	Hartkoorn RC, Uplekar S, Cole ST. Cross-resistance between clofazimine and bedaquiline through upregulation of MmpL5 in Mycobacterium tuberculosis. Antimicrob Agents Chemother, 2014, 58(5):2979-2981. doi:10.1128/AAC.00037-14. pmid: 24590481
[15]	Somoskovi A, Bruderer V, Hömke R, et al. A mutation associated with clofazimine and bedaquiline cross-resistance in MDR-TB following bedaquiline treatment. Eur Respir J, 2015, 45(2):554-557. doi:10.1183/09031936.00142914. pmid: 25359333
[16]	Omar SV, Ismail F, Ndjeka N, et al. Bedaquiline-Resistant Tuberculosis Associated with Rv0678 Mutations. N Engl J Med, 2022, 386(1):93-94. doi:10.1056/NEJMc2103049.
[17]	Ntziora F, Falagas ME. Linezolid for the treatment of patients with mycobacterial infections: a systematic review. Int J Tuberc Lung Dis, 2007, 11(6):606-611. pmid: 17519090
[18]	Migliori GB, Eker B, Richardson MD, et al. A retrospective TBNET assessment of linezolid safety, tolerability and efficacy in multidrug-resistant tuberculosis. Eur Respir J, 2009, 34(2): 387-393. doi:10.1183/09031936.00009509. pmid: 19282348
[19]	Park IN, Hong SB, Oh YM, et al. Efficacy and tolerability of daily-half dose linezolid in patients with intractable multidrug-resistant tuberculosis. J Antimicrob Chemother, 2006, 58(3):701-704. doi:10.1093/jac/dkl298.
[20]	Koh WJ, Kwon OJ, Gwak H, et al. Daily 300 mg dose of linezolid for the treatment of intractable multidrug-resistant and extensively drug-resistant tuberculosis. J Antimicrob Chemother, 2009, 64(2): 388-391. doi:10.1093/jac/dkp171.
[21]	Sotgiu G, Centis R, D’Ambrosio L, et al. Efficacy, safety and tolerability of linezolid containing regimens in treating MDR-TB and XDR-TB: systematic review and meta-analysis. Eur Respir J, 2012, 40(6):1430-1442. doi:10.1183/09031936.00022912. pmid: 22496332
[22]	Singh B, Cocker D, Ryan H, et al. Linezolid for drug-resistant pulmonary tuberculosis. Cochrane Database Syst Rev, 2019, 3(3):CD012836. doi:10.1002/14651858.CD012836.pub2.
[23]	Zhou W, Nie W, Wang Q, et al. Linezolid Pharmacokinetics/Pharmacodynamics-Based Optimal Dosing for Multidrug-Resistant Tuberculosis. Int J Antimicrob Agents, 2022, 59(6):106589. doi:10.1016/j.ijantimicag.2022.106589.
[24]	Ginsburg AS, Grosset JH, Bishai WR. Fluoroquinolones, tuberculosis, and resistance. Lancet Infect Dis, 2003, 3(7): 432-442. doi:10.1016/s1473-3099(03)00671-6. pmid: 12837348
[25]	Caminero JA, World Health Organization, American Thoracic Society, et al. Treatment of multidrug-resistant tuberculosis: evidence and controversies. Int J Tuberc Lung Dis, 2006, 10(8): 829-837. pmid: 16898365
[26]	World Health Organization. Guidelines for the programmatic management of drug-resistant tuberculosis. Geneva: World Health Organization, 2006.
[27]	Khaliq Y, Zhanel GG. Fluoroquinolone-associated tendinopathy: a critical review of the literature. Clin Infect Dis, 2003, 36(11):1404-1410. doi:10.1086/375078. pmid: 12766835
[28]	Fish DN. Fluoroquinolone adverse effects and drug interactions. Pharmacotherapy, 2001, 21(10 Pt 2): 253S-272S. doi:10.1592/phco.21.16.253s.33993. pmid: 11642691
[29]	Maitre T, Petitjean G, Chauffour A, et al. Are moxifloxacin and levofloxacin equally effective to treat XDR tuberculosis?. J Antimicrob Chemother, 2017, 72(8):2326-2333. doi:10.1093/jac/dkx150. pmid: 28535203
[30]	Mirnejad R, Asadi A, Khoshnood S, et al. Clofazimine: A useful antibiotic for drug-resistant tuberculosis. Biomed Pharmacother, 2018, 105: 1353-1359. doi:10.1016/j.biopha.2018.06.023. pmid: 30021373
[31]	Peloquin CA, Davies GR. The Treatment of Tuberculosis. Clin Pharmacol Ther, 2021, 110(6):1455-1466. doi:10.1002/cpt.2261. pmid: 33837535
[32]	Alghamdi WA, Alsultan A, Al-Shaer MH, et al. Cycloserine Population Pharmacokinetics and Pharmacodynamics in Patients with Tuberculosis. Antimicrob Agents Chemother, 2019, 63(5):e00055-19. doi:10.1128/AAC.00055-19.
[33]	Curry International Tuberculosis Center. Drug-Resistant Tuberculosis:A Survival Guide for Clinicians, 3rd Ed. Washington, DC: Curry International Tuberculosis Center, 2016.
[34]	Court R, Centner CM, Chirehwa M, et al. Neuropsychiatric toxicity and cycloserine concentrations during treatment for multidrug-resistant tuberculosis. Int J Infect Dis, 2021, 105: 688-694. doi:10.1016/j.ijid.2021.03.001. pmid: 33684562
[35]	Gler MT, Skripconoka V, Sanchez-Garavito E, et al. Delamanid for multidrug-resistant pulmonary tuberculosis. N Engl J Med, 2012, 366(23):2151-2160. doi:10.1056/NEJMoa1112433.
[36]	von Groote-Bidlingmaier F, Patientia R, Sanchez E, et al. Efficacy and safety of delamanid in combination with an optimised background regimen for treatment of multidrug-resistant tuberculosis: a multicentre, randomised, double-blind, placebo-controlled, parallel group phase 3 trial. Lancet Respir Med, 2019, 7(3): 249-259. doi:10.1016/S2213-2600(18)30426-0. pmid: 30630778
[37]	Lardizabal AA, Khan AN, Bamrah Morris S, et al. Notes from the Field: Acquisition of Delamanid Under a Compassionate Use Program for Extensively Drug-Resistant Tuberculosis-United States, 2017. MMWR Morb Mortal Wkly Rep, 2018, 67(35):996-997. doi:10.15585/mmwr.mm6735a6.
[38]	World Health Organization. The use of delamanid in the treatment of multidrug-resistant tuberculosis: Interim policy guidelines. Geneva: World Health Organization, 2014.
[39]	Dooley KE, Rosenkranz SL, Conradie F, et al. QT effects of bedaquiline, delamanid, or both in patients with rifampicin-resistant tuberculosis: a phase 2, open-label, randomised, controlled trial. Lancet Infect Dis, 2021, 21(7):975-983. doi:10.1016/S1473-3099(20)30770-2. pmid: 33587897
[40]	Diacon AH, Dawson R, von Groote-Bidlingmaier F, et al. 14-day bactericidal activity of PA-824, bedaquiline, pyrazinamide, and moxifloxacin combinations: a randomised trial. Lancet, 2012, 380(9846):986-993. doi:10.1016/S0140-6736(12)61080-0. pmid: 22828481
[41]	Diacon AH, Dawson R, von Groote-Bidlingmaier F, et al. Bactericidal activity of pyrazinamide and clofazimine alone and in combinations with pretomanid and bedaquiline. Am J Respir Crit Care Med, 2015, 191(8):943-953. doi:10.1164/rccm.201410-1801OC.
[42]	Dawson R, Diacon AH, Everitt D, et al. Efficiency and safety of the combination of moxifloxacin, pretomanid (PA-824), and pyrazinamide during the first 8 weeks of antituberculosis treatment: a phase 2b, open-label, partly randomised trial in patients with drug-susceptible or drug-resistant pulmonary tuberculosis. Lancet, 2015, 385(9979):1738-1747. doi:10.1016/S0140-6736(14)62002-X. pmid: 25795076

耐药肺结核短程治疗方案面临的困难与挑战

Difficulties and challenges faced by short-term treatment regimen for drug-resistant pulmonary tuberculosis

RichHTML

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献 42

相关文章 15

编辑推荐

Metrics

本文评价

友情链接

[1]	中国防痨协会结核病控制专业分会, 中国防痨协会青年分会, 《中国防痨杂志》编辑委员会. 中国结核病数字服药依从性技术应用指南[J]. 中国防痨杂志, 2025, 47(4): 385-397.
[2]	黄伟强, 袁楚楚, 陈星星, 商会会, 徐雅, 胡明. 康替唑胺替代利奈唑胺方案治疗耐药结核病一例[J]. 中国防痨杂志, 2025, 47(4): 527-530.
[3]	中国人民解放军总医院第八医学中心结核病医学部, 《中国防痨杂志》编辑委员会, 中国医疗保健国际交流促进会, 结核病防治分会基础和临床学部. 结核性腹膜炎多学科诊疗专家共识[J]. 中国防痨杂志, 2025, 47(3): 243-257.
[4]	杨子仪, 陈素婷. 贝达喹啉耐药及耐药诊断的研究进展[J]. 中国防痨杂志, 2025, 47(3): 374-379.
[5]	中国防痨协会《中国防痨杂志》编辑委员会首都医科大学附属北京胸科医院/北京市结核病胸部肿瘤研究所 Inspire⁃CODA研究组. 康替唑胺治疗结核病专家共识[J]. 中国防痨杂志, 2025, 47(2): 123-129.
[6]	李雪莲, 张红燕, 王隽, 王庆枫, 马丽萍, 初乃惠, 聂文娟. 耐药肺结核患者超疗程使用德拉马尼的安全性分析[J]. 中国防痨杂志, 2025, 47(2): 164-168.
[7]	《脊柱结核并发HIV/AIDS患者诊断及治疗专家共识》编写组, 中国防痨协会骨关节结核专业分会, 中国性病艾滋病防治协会艾滋病外科专业委员会, 中国西部骨结核联盟, 中国华北骨结核联盟. 脊柱结核并发HIV/AIDS患者诊断及治疗专家共识(第2版)[J]. 中国防痨杂志, 2025, 47(1): 1-11.
[8]	倪健健. 耐多药肺结核治疗效果评价[J]. 中国防痨杂志, 2024, 46(S2): 13-15.
[9]	耿子妹, 王潮虹, 龙嗣博, 郑迈克, 施亦衡, 孙勇, 赵艳, 王桂荣. 重症肺结核患者病原学阳性率及利福平耐药结果分析[J]. 中国防痨杂志, 2024, 46(9): 1050-1055.
[10]	王飞, 华朵, 郭建建, 刘畅, 韩璐, 任易. 2021—2023年武汉地区非结核分枝杆菌肺病患者特征分析[J]. 中国防痨杂志, 2024, 46(9): 1069-1076.
[11]	李杨, 孙峰, 张文宏. 结核病短程治疗研究:回顾与展望[J]. 中国防痨杂志, 2024, 46(9): 991-997.
[12]	李志丽, 刘宇红. 《世界卫生组织结核病整合指南模块6: 结核病及其共患病-HIV》解读[J]. 中国防痨杂志, 2024, 46(8): 869-873.
[13]	杨梁梓, 张培泽, 卢水华. 世界卫生组织《耐药结核病和丙型病毒性肝炎治疗的联合管理(2024快讯版)》解读[J]. 中国防痨杂志, 2024, 46(8): 874-876.
[14]	薛毅, 梁倩, 齐浩然, 梁瑞霞, 黄海荣. 不同技术检测利福平耐药预测耐多药结核病的可靠性分析[J]. 中国防痨杂志, 2024, 46(8): 892-896.
[15]	于兰, 陈双双, 王嫩寒, 田丽丽, 赵琰枫, 樊瑞芳, 刘海灿, 李传友, 代小伟. 利福平耐药结核分枝杆菌对氟喹诺酮类药物表型耐药与其基因突变的一致性研究[J]. 中国防痨杂志, 2024, 46(8): 942-950.